Limits...
Combined effect of bisphosphonate and recombinant human bone morphogenetic protein 2 on bone healing of rat calvarial defects.

Kim HC, Song JM, Kim CJ, Yoon SY, Kim IR, Park BS, Shin SH - Maxillofac Plast Reconstr Surg (2015)

Bottom Line: There were significant decrease of bone formation area (p < 0.05) between group 4 and group 2, 3.However, receptor activator of nuclear factor κB ligand (RANKL) decreased with time dependent except group 4.Low concentration bisphosphonate and rhBMP-2 have synergic effect on bone regeneration and this is result from the decreased activity of RANKL of osteoblast.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University, 626-787 Yangsan, Mulgeum-eup Korea.

ABSTRACT

Background: This study aimed to investigate new bone formation using recombinant human bone morphogenetic protein 2 (rhBMP-2) and locally applied bisphosphonate in rat calvarial defects.

Methods: Thirty-six rats were studied. Two circular 5 mm diameter bony defect were formed in the calvaria using a trephine bur. The bony defect were grafted with Bio-Oss® only (group 1, n = 9), Bio-Oss® wetted with rhBMP-2 (group 2, n = 9), Bio-Oss® wetted with rhBMP-2 and 1 mM alendronate (group 3, n = 9) and Bio-Oss® wetted with rhBMP-2 and 10 mM alendronate (group 4, n = 9). In each group, three animals were euthanized at 2, 4 and 8 weeks after surgery, respectively. The specimens were then analyzed by histology, histomorphometry and immunohistochemistry analysis.

Results: There were significant decrease of bone formation area (p < 0.05) between group 4 and group 2, 3. Group 3 showed increase of new bone formation compared to group 2. In immunohistochemistry, collagen type I and osteoprotegerin (OPG) didn't show any difference. However, receptor activator of nuclear factor κB ligand (RANKL) decreased with time dependent except group 4.

Conclusion: Low concentration bisphosphonate and rhBMP-2 have synergic effect on bone regeneration and this is result from the decreased activity of RANKL of osteoblast.

No MeSH data available.


Related in: MedlinePlus

RANKL antibody reaction of grafted sites. a 2 week group 1; b 2week group 2; c 2week group 3; d 2 week group 4; e 4 week group 1; f 4 week group 2; g 4 week group 3; h 4 week group 4; i 8 week group 1; j 8 week group 2; k 8 week group 3; l 8 week group 4. Magnification X 100
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4488498&req=5

Fig6: RANKL antibody reaction of grafted sites. a 2 week group 1; b 2week group 2; c 2week group 3; d 2 week group 4; e 4 week group 1; f 4 week group 2; g 4 week group 3; h 4 week group 4; i 8 week group 1; j 8 week group 2; k 8 week group 3; l 8 week group 4. Magnification X 100

Mentions: In the case of RANKL, expression of RANKL was decreased with time dependant except group 4. Manifestation seems to be slightly reduced in the 2 and 4 week stages in group 3. It continues to be manifested moderate in group 4 (Fig. 6, Table 4).Fig. 6


Combined effect of bisphosphonate and recombinant human bone morphogenetic protein 2 on bone healing of rat calvarial defects.

Kim HC, Song JM, Kim CJ, Yoon SY, Kim IR, Park BS, Shin SH - Maxillofac Plast Reconstr Surg (2015)

RANKL antibody reaction of grafted sites. a 2 week group 1; b 2week group 2; c 2week group 3; d 2 week group 4; e 4 week group 1; f 4 week group 2; g 4 week group 3; h 4 week group 4; i 8 week group 1; j 8 week group 2; k 8 week group 3; l 8 week group 4. Magnification X 100
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4488498&req=5

Fig6: RANKL antibody reaction of grafted sites. a 2 week group 1; b 2week group 2; c 2week group 3; d 2 week group 4; e 4 week group 1; f 4 week group 2; g 4 week group 3; h 4 week group 4; i 8 week group 1; j 8 week group 2; k 8 week group 3; l 8 week group 4. Magnification X 100
Mentions: In the case of RANKL, expression of RANKL was decreased with time dependant except group 4. Manifestation seems to be slightly reduced in the 2 and 4 week stages in group 3. It continues to be manifested moderate in group 4 (Fig. 6, Table 4).Fig. 6

Bottom Line: There were significant decrease of bone formation area (p < 0.05) between group 4 and group 2, 3.However, receptor activator of nuclear factor κB ligand (RANKL) decreased with time dependent except group 4.Low concentration bisphosphonate and rhBMP-2 have synergic effect on bone regeneration and this is result from the decreased activity of RANKL of osteoblast.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University, 626-787 Yangsan, Mulgeum-eup Korea.

ABSTRACT

Background: This study aimed to investigate new bone formation using recombinant human bone morphogenetic protein 2 (rhBMP-2) and locally applied bisphosphonate in rat calvarial defects.

Methods: Thirty-six rats were studied. Two circular 5 mm diameter bony defect were formed in the calvaria using a trephine bur. The bony defect were grafted with Bio-Oss® only (group 1, n = 9), Bio-Oss® wetted with rhBMP-2 (group 2, n = 9), Bio-Oss® wetted with rhBMP-2 and 1 mM alendronate (group 3, n = 9) and Bio-Oss® wetted with rhBMP-2 and 10 mM alendronate (group 4, n = 9). In each group, three animals were euthanized at 2, 4 and 8 weeks after surgery, respectively. The specimens were then analyzed by histology, histomorphometry and immunohistochemistry analysis.

Results: There were significant decrease of bone formation area (p < 0.05) between group 4 and group 2, 3. Group 3 showed increase of new bone formation compared to group 2. In immunohistochemistry, collagen type I and osteoprotegerin (OPG) didn't show any difference. However, receptor activator of nuclear factor κB ligand (RANKL) decreased with time dependent except group 4.

Conclusion: Low concentration bisphosphonate and rhBMP-2 have synergic effect on bone regeneration and this is result from the decreased activity of RANKL of osteoblast.

No MeSH data available.


Related in: MedlinePlus